Cantabio Pharmaceuticals, Inc. (OTCPK:CTBO) announced that it has entered into a securities purchase agreement for a private placement of secured convertible debentures with new investor, YA II PN, LTD., a fund managed by Yorkville Advisors Global LP for gross proceeds of $600,000 on January 25, 2017. The debenture carries a coupon of 5% per annum, a maturity date of one year after issuance, and may be converted at any time on or prior to maturity at the lower of $0.3107 or 93% of the average of the three lowest daily volume weighted average prices during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as it is not in default under the debenture, the conversion price may never be less than $0.10. The company will issue securities pursuant to exemption under Regulation D. The company will pay a monitoring fee in the amount of 7% of the purchase price of each closing to YA Global II SPV, LLC, an affiliate of the investor. The investor will not hold more than 4.99% stake in the company upon conversion, provided that such limitation may be waived by the holder with 65 days’ notice. On the same date, the company announced that it has received $300,000 in its first tranche. The company will close a second tranche of $150,000 for within three days of the date of filing registration statement, and a final tranche of $150,000 within three days of the date on which the United States Securities and Exchange Commission declares the registration statement effective.